The relationship of serum lactate level with in-hospital mortality after transcatheter aortic valve implantation
Biomarkers in Medicine, cilt.19, sa.12, ss.481-489, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 19 Sayı: 12
- Basım Tarihi: 2025
- Doi Numarası: 10.1080/17520363.2025.2517524
- Dergi Adı: Biomarkers in Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
- Sayfa Sayıları: ss.481-489
- Anahtar Kelimeler: Transcatheter aortic valve implantation, transcatheter aortic valve replacement, aortic valve stenosis, mortality, lactate
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: This study assesses the influence of early hyperlactatemia after the transcatheter aortic valve implantation (TAVI) procedure on subsequent outcomes. Methods: Adult patients undergoing elective percutaneous TAVI between 2012 and 2022 in a single tertiary cardiac center were retrospectively included. Peak post-procedure lactate level within 24-h was recorded for 284 patients included in the study. The primary outcome measured was 30-day mortality. Results: 19 patients (6.6%) experienced 30-day mortality. Patients with mortality were characterized by advanced age (p = 0.022) and higher lactate levels after the procedure (5.4 ± 5.4 mmol/L vs 1.3 ± 0.6 mmol/L, p < 0.001). Post-procedure hyperlactatemia was an independent predictor of mortality (OR 3.95, 95% CI 1.35–11.60, p = 0.012). ROC analysis revealed 1.54 mmol/L as a cutoff for mortality with 85.7% specificity and 68.4% sensitivity. Conclusion: The initial 24-hour lactate levels seem to play a valuable role in predicting the likelihood of surviving during the hospital stay after the implantation procedure. Further investigation is required to ascertain the optimal strategies for managing early post-procedure hyperlactatemia in the TAVI population.